Salix (Bausch Health) Signs an Exclusive License Agreement with Mitsubishi Tanabe for its MT-1303 (amiselimod)

Shots:

• MTPC to receive upfront, development & regulatory milestones and royalties on sales. Bausch Health to get exclusive WW rights to develop & commercialize MT-1303 (Ex-Japan & few other countries in Asia) in all fields (Ex. neurology, rheumatology and certain rare dermatology diseases)
• Bausch plans to initiate the development of MTPC’s MT-1303 (amiselimod) in ulcerative colitis. MTPC will utilize the clinical data conducted by Bausch for regulatory approval and further commercialize it in Japan and certain other countries
• MT-1303 (amiselimod) targets sphingosine-1-phosphate (S1P) receptor to retain lymphocytes sequestered in the lymph nodes and is evaluated in clinical studies for multiple sclerosis, psoriasis, Crohn’s disease and systemic lupus erythematosus across Europe & Japan

Click here to read full press release/ article | Ref: Mitsubishi Tanabe | Image: Financial Post